{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:37:33Z","timestamp":1788028653848,"version":"build-2784847793"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/fpc.0000000000000211","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T10:02:05Z","timestamp":1456826525000},"page":"225-234","source":"Crossref","is-referenced-by-count":107,"title":["Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population"],"prefix":"10.1097","volume":"26","author":[{"given":"Wichittra","family":"Tassaneeyakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napat","family":"Prabmeechai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thachanan","family":"Kongpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinya","family":"Konyoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pansu","family":"Chumworathayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Tiamkao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanee","family":"Khunarkornsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongkiat","family":"Kulkantrakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niwat","family":"Saksit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontaya","family":"Nakkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompong","family":"Satapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suda","family":"Vannaprasaht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisara","family":"Sangviroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surakameth","family":"Mahasirimongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuanjun","family":"Wichukchinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticha","family":"Rerkpattanapipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wongwiwat","family":"Tassaneeyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210213","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(04)00935-4","article-title":"Current drug treatment of epilepsy in adults","volume":"3","author":"McCorry","year":"2004","journal-title":"Lancet Neurol"},{"key":"R2-4-20210213","first-page":"CD001911","article-title":"Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review","volume":"8","author":"Nolan","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-4-20210213","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R4-4-20210213","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"key":"R5-4-20210213","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"R6-4-20210213","first-page":"625","article-title":"Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy","volume":"13","author":"Paulmann","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"R7-4-20210213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"R8-4-20210213","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM195006082422304","article-title":"Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis","volume":"242","author":"Chaiken","year":"1950","journal-title":"N Engl J Med"},{"key":"R9-4-20210213","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"R10-4-20210213","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R11-4-20210213","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"R12-4-20210213","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1533-2500.2011.00479.x","article-title":"HLA-B*1502 strongly predicts carbamazepine-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain","volume":"12","author":"Kulkantrakorn","year":"2012","journal-title":"Pain Pract"},{"key":"R13-4-20210213","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"R14-4-20210213","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens\u2013Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"R15-4-20210213","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R16-4-20210213","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"R17-4-20210213","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"R18-4-20210213","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1001\/jama.2008.890","article-title":"FDA: epilepsy drugs may carry skin risks for Asians","volume":"300","author":"Kuehn","year":"2008","journal-title":"JAMA"},{"key":"R19-4-20210213","first-page":"2","article-title":"Phenytoin: risk of Stevens-Johnson syndrome associated with HLA-B1502 allele in patients of Thai or Han Chinese ethnic origin.","volume":"3","year":"2010","journal-title":"Drug Safety Update"},{"key":"R20-4-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/03009748709102191","article-title":"Clinical aspects of skin reactions to NSAIDs","volume":"65","author":"Roujeau","year":"1987","journal-title":"Scand J Rheumatol Suppl"},{"key":"R21-4-20210213","doi-asserted-by":"crossref","first-page":"693.e1","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: Part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R22-4-20210213","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"R23-4-20210213","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R24-4-20210213","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R25-4-20210213","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R26-4-20210213","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1399-0039.2010.01448.x","article-title":"HLA class I and II alleles and haplotypes in ethnic Northeast Thais","volume":"75","author":"Romphruk","year":"2010","journal-title":"Tissue Antigens"},{"key":"R27-4-20210213","first-page":"478","article-title":"HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity","volume":"5","author":"Puangpetch","year":"2014","journal-title":"Front Genet"},{"key":"R28-4-20210213","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2133\/dmpk.DMPK-10-RG-059","article-title":"Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin","volume":"25","author":"Sangviroon","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"R29-4-20210213","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/pai.12058","article-title":"Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children","volume":"24","author":"Manuyakorn","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"R30-4-20210213","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5694\/mja12.10477","article-title":"Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele","volume":"197","author":"Harding","year":"2012","journal-title":"Med J Aust"},{"key":"R31-4-20210213","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0920-1211(99)00017-0","article-title":"A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin","volume":"35","author":"Rettie","year":"1999","journal-title":"Epilepsy Res"},{"key":"R32-4-20210213","first-page":"494","article-title":"Co-regulation of phenytoin and tolbutamide metabolism in humans","volume":"34","author":"Tassaneeyakul","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"R33-4-20210213","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R34-4-20210213","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/jpet.109.150706","article-title":"CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry","volume":"329","author":"Mosher","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"R35-4-20210213","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/tpj.2012.19","article-title":"Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms","volume":"13","author":"Dorado","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R36-4-20210213","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0009-9236(01)95478-5","article-title":"Severe phenytoin intoxication in a subject homozygous for CYP2C9*3","volume":"70","author":"Brandolese","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R37-4-20210213","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00228-004-0753-0","article-title":"Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions","volume":"60","author":"Lee","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-4-20210213","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/jnnp.47.6.642","article-title":"Serum anticonvulsant concentrations and the risk of drug induced skin eruptions","volume":"47","author":"Chadwick","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R39-4-20210213","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/bmj.1.6127.1583","article-title":"High incidence of a concentration-dependent skin reaction in children treated with phenytoin","volume":"1","author":"Wilson","year":"1978","journal-title":"Br Med J"},{"key":"R40-4-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003088-199018020-00004","article-title":"Pharmacokinetic drug interactions with phenytoin (part II)","volume":"18","author":"Nation","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"R41-4-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003088-199018020-00004","article-title":"Pharmacokinetic drug interactions with phenytoin (part II)","volume":"18","author":"Nation","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"R42-4-20210213","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/B978-0-7020-4086-3.00027-8","article-title":"Use of antiepileptic drugs in hepatic and renal disease","volume":"119","author":"Asconap\u00e9","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"R43-4-20210213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000335613","article-title":"Genetics and the potential for predictive tests in adverse drug reactions","volume":"97","author":"Pirmohamed","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"R44-4-20210213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330903427969","article-title":"Genetic predisposition of life-threatening antiepileptic-induced skin reactions","volume":"9","author":"Chung","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"R45-4-20210213","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R46-4-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256308","article-title":"Successful translation of pharmacogenetics into the clinic: the abacavir example","volume":"13","author":"Phillips","year":"2009","journal-title":"Mol Diagn Ther"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:07:29Z","timestamp":1718388449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201605000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000211","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}